The Interaction of DNA Repair Factors ASCC2 and ASCC3 Is Affected by Somatic Cancer Mutations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hypopituitarism May Be an Additional Feature of SIM1 and POU3F2 Containing 6Q16 Deletions in Children with Early Onset Obesity
Open Access Journal of Pediatric Endocrinology Case Report Hypopituitarism may be an Additional Feature of SIM1 and POU3F2 Containing 6q16 Deletions in Children with Early Onset Obesity Rutteman B1, De Rademaeker M2, Gies I1, Van den Bogaert A2, Zeevaert R1, Vanbesien J1 and De Abstract Schepper J1* Over the past decades, 6q16 deletions have become recognized as a 1Department of Pediatric Endocrinology, UZ Brussel, frequent cause of the Prader-Willi-like syndrome. Involvement of SIM1 in the Belgium deletion has been linked to the development of obesity. Although SIM1 together 2Department of Genetics, UZ Brussel, Belgium with POU3F2, which is located close to the SIM1 locus, are involved in pituitary *Corresponding author: De Schepper J, Department development and function, pituitary dysfunction has not been reported frequently of Pediatric Endocrinology, UZ Brussel, Belgium in cases of 6q16.1q16.3 deletion involving both genes. Here we report on a case of a girl with typical Prader-Willi-like symptoms including early-onset Received: December 23, 2016; Accepted: February 21, hyperphagic obesity, hypotonia, short hands and feet and neuro-psychomotor 2017; Published: February 22, 2017 development delay. Furthermore, she suffered from central diabetes insipidus, central hypothyroidism and hypocortisolism. Her genetic defect is a 6q16.1q16.3 deletion, including SIM1 and POU3F2. We recommend searching for a 6q16 deletion in children with early onset hyperphagic obesity associated with biological signs of hypopituitarism and/or polyuria-polydipsia syndrome. The finding of a combined SIM1 and POU3F2 deletion should prompt monitoring for the development of hypopituitarism, if not already present at diagnosis. Keywords: 6q16 deletion; SIM1; POU3F2; Prader-Willi-like syndrome; Hypopituitarism Introduction insipidus and of some specific pituitary hormone deficiencies in children with a combined SIM1 and POU3F2 deficiency. -
S41467-020-18249-3.Pdf
ARTICLE https://doi.org/10.1038/s41467-020-18249-3 OPEN Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain Lei Zhao1,2,17, Zhongqi Li 1,2,17, Joaquim S. L. Vong2,3,17, Xinyi Chen1,2, Hei-Ming Lai1,2,4,5,6, Leo Y. C. Yan1,2, Junzhe Huang1,2, Samuel K. H. Sy1,2,7, Xiaoyu Tian 8, Yu Huang 8, Ho Yin Edwin Chan5,9, Hon-Cheong So6,8, ✉ ✉ Wai-Lung Ng 10, Yamei Tang11, Wei-Jye Lin12,13, Vincent C. T. Mok1,5,6,14,15 &HoKo 1,2,4,5,6,8,14,16 1234567890():,; The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovas- cular dysfunction in neurodegenerative diseases remain elusive. Here, we report zonation- dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which pro- minently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood–brain barrier (BBB) and glucose/energy metabolism especially in capillary ECs (capECs). An overrepresentation of Alzheimer disease (AD) GWAS genes is evident among the human orthologs of the differentially expressed genes of aged capECs, while comparative analysis revealed a subset of concordantly downregulated, functionally important genes in human AD brains. Treatment with exenatide, a glucagon-like peptide-1 receptor agonist, strongly reverses aged mouse brain EC transcriptomic changes and BBB leakage, with associated attenuation of microglial priming. We thus revealed tran- scriptomic alterations underlying brain EC ageing that are complex yet pharmacologically reversible. -
Supplementary Information
Supplementary Information Table S1. Gene Ontology analysis of affected biological processes/pathways/themes in H1 hESCs based on sets of statistically significant differentially expressed genes. Exposures Overrepresented Categories (Upregulation) EASE Score Negative regulation of cell differentiation 0.0049 Lipid biosynthetic process 0.015 Negative regulation of cell proliferation 0.02 5 cGy, 2 h Transcription factor binding 0.037 Regulation of apoptosis 0.038 Positive regulation of anti-apoptosis 0.048 P53 signaling pathway 4.2 × 10−10 Positive regulation of apoptosis 7.5 × 10−8 Response to DNA damage stimulus 1.5 × 10−6 Cellular response to stress 9.6 × 10−6 1 Gy, 2 h Negative regulation of cell proliferation 9.8 × 10−6 Cell cycle arrest 7.0 × 10−4 Negative regulation of cell differentiation 1.5 × 10−3 Regulation of protein kinase activity 0.011 I-kappaB kinase/NF-kappaB cascade 0.025 Metallothionein superfamily 9.9 × 10−18 Induction of apoptosis 8.8 × 10−5 DNA damage response 2.6 × 10−4 1 Gy, 16 h Positive regulation of anti-apoptosis 0.001 Positive regulation of cell death 0.005 Cellular response to stress 0.012 Exposures Overrepresented Categories (Downregulation) EASE Score Alternative splicing 0.016 1 Gy, 2 h Chromatin organization 0.020 Chromatin assembly 2.0 × 10−6 Cholesterol biosynthesis 5.1 × 10−5 Macromolecular complex assembly 9.3 × 10−4 1 Gy, 16 h PPAR signaling pathway 0.007 Hemopoietic organ development 0.033 Immune system development 0.040 S2 Table S2. Gene Ontology analysis of affected biological processes/pathways/themes in H7 based on sets of statistically significant differentially expressed genes. -
Multiomic Analysis of the UV-Induced DNA Damage Response
Resource Multiomic Analysis of the UV-Induced DNA Damage Response Graphical Abstract Authors Stefan Boeing, Laura Williamson, Vesela Encheva, ..., Michael Howell, Ambrosius P. Snijders, Jesper Q. Svejstrup Correspondence [email protected] In Brief Boeing et al. investigate the UV-induced DNA damage response by combining a range of proteomic and genomic screens. A function in this response for the melanoma driver STK19 as well as a number of other factors are uncovered. Highlights d A multiomic screening approach examines the UV-induced DNA damage response d Multiple factors are connected to the transcription-related DNA damage response d Melanoma gene STK19 is required for a normal DNA damage response Boeing et al., 2016, Cell Reports 15, 1597–1610 May 17, 2016 ª 2016 The Author(s) http://dx.doi.org/10.1016/j.celrep.2016.04.047 Cell Reports Resource Multiomic Analysis of the UV-Induced DNA Damage Response Stefan Boeing,1,5 Laura Williamson,1 Vesela Encheva,2 Ilaria Gori,3 Rebecca E. Saunders,3 Rachael Instrell,3 Ozan Aygun,€ 1,7 Marta Rodriguez-Martinez,1 Juston C. Weems,4 Gavin P. Kelly,5 Joan W. Conaway,4,6 Ronald C. Conaway,4,6 Aengus Stewart,5 Michael Howell,3 Ambrosius P. Snijders,2 and Jesper Q. Svejstrup1,* 1Mechanisms of Transcription Laboratory, the Francis Crick Institute, Clare Hall Laboratories, South Mimms EN6 3LD, UK 2Protein Analysis and Proteomics Laboratory, the Francis Crick Institute, Clare Hall Laboratories, South Mimms EN6 3LD, UK 3High Throughput Screening Laboratory, the Francis Crick Institute, 44 Lincoln’s -
Development of Novel Analysis and Data Integration Systems to Understand Human Gene Regulation
Development of novel analysis and data integration systems to understand human gene regulation Dissertation zur Erlangung des Doktorgrades Dr. rer. nat. der Fakult¨atf¨urMathematik und Informatik der Georg-August-Universit¨atG¨ottingen im PhD Programme in Computer Science (PCS) der Georg-August University School of Science (GAUSS) vorgelegt von Raza-Ur Rahman aus Pakistan G¨ottingen,April 2018 Prof. Dr. Stefan Bonn, Zentrum f¨urMolekulare Neurobiologie (ZMNH), Betreuungsausschuss: Institut f¨urMedizinische Systembiologie, Hamburg Prof. Dr. Tim Beißbarth, Institut f¨urMedizinische Statistik, Universit¨atsmedizin, Georg-August Universit¨at,G¨ottingen Prof. Dr. Burkhard Morgenstern, Institut f¨urMikrobiologie und Genetik Abtl. Bioinformatik, Georg-August Universit¨at,G¨ottingen Pr¨ufungskommission: Prof. Dr. Stefan Bonn, Zentrum f¨urMolekulare Neurobiologie (ZMNH), Referent: Institut f¨urMedizinische Systembiologie, Hamburg Prof. Dr. Tim Beißbarth, Institut f¨urMedizinische Statistik, Universit¨atsmedizin, Korreferent: Georg-August Universit¨at,G¨ottingen Prof. Dr. Burkhard Morgenstern, Weitere Mitglieder Institut f¨urMikrobiologie und Genetik Abtl. Bioinformatik, der Pr¨ufungskommission: Georg-August Universit¨at,G¨ottingen Prof. Dr. Carsten Damm, Institut f¨urInformatik, Georg-August Universit¨at,G¨ottingen Prof. Dr. Florentin W¨org¨otter, Physikalisches Institut Biophysik, Georg-August-Universit¨at,G¨ottingen Prof. Dr. Stephan Waack, Institut f¨urInformatik, Georg-August Universit¨at,G¨ottingen Tag der m¨undlichen Pr¨ufung: der 30. M¨arz2018 -
ASCC2 Antibody
Product Datasheet ASCC2 Antibody Catalog No: #AB37399 Orders: [email protected] Description Support: [email protected] Product Name ASCC2 Antibody Host Species Rabbit Clonality Polyclonal Purification Antigen affinity purification. Applications WB Species Reactivity Hu Ms Specificity The antibody detects endogenous levels of total ASCC2 protein. Immunogen Type Peptide Immunogen Description Synthetic peptide corresponding to a region derived from internal residues of human activating signal cointegrator 1 complex subunit 2 Target Name ASCC2 Other Names p100; ASC1p100 Accession No. Swiss-Prot#: Q9H1I8NCBI Gene ID: 84164Gene Accssion: NP_115580 SDS-PAGE MW 86kd Concentration 2.2mg/ml Formulation Rabbit IgG in pH7.3 PBS, 0.05% NaN3, 50% Glycerol. Storage Store at -20°C Application Details Western blotting: 1:200-1:1000 Images Gel: 6%SDS-PAGE Lysates (from left to right): 293T, A431 and hepG2 cell Amount of lysate: 40ug per lane Primary antibody: 1/367 dilution Secondary antibody dilution: 1/8000 Exposure time: 20 seconds Background ASCC2 (activating signal cointegrator 1 complex subunit 2), also known as ASC1P100, is a 757 amino acid protein that is ubiquitously expressed and contains one CUE domain.?The gene encoding ASCC2 maps to human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. Mutations in several of the genes that map to chromosome 22 are involved in the development of Phelan-McDermid syndrome, Neurofibromatosis type 2, autism and schizophrenia. Additionally, translocations between chromosomes 9 and 22 may lead to the formation of the Address: 8400 Baltimore Ave. Suite 302 College Park MD 20740 USA http://www.abscitech.com 1 Philadelphia Chromosome and the subsequent production of the novel fusion protein BCR-Abl, a potent cell proliferation activator found in several types of leukemias. -
Supplementary Tables 1-6 Supplementary Table 1
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways Supplementary Tables 1-6 Supplementary Table 1. Meta-analysis heterogeneity and meta-regression results for nevus association using the R metafor package. The meta- regression included mean age in the study, mean absolute latitude and nevus measurement method as moderators. In the meta-regression, I2 is the estimated percentage of sampling variance due to heterogeneity between studies, R2 the percentage explained by the moderator variables, and H2 the percentage unexplained residual heterogeneity. QM P is the P-value from the test for the contribution of moderators, and QE P, the P-value for the test for residual heterogeneity. Random Effects (REML) meta-analysis Meta-regression (covariates: mean age, latitude, nevus measure) SNP Gene/Interval 2 2 2 Z P Het P H R I QE P QM P rs72704658 SETDB1 -1.783 7.46E-02 0.696 1.029 0.000 2.774 0.307 0.978 rs2695237 PARP1 -2.902 3.71E-03 0.525 1.000 95.683 0.022 0.251 0.871 rs4670813 CYP1B1 -5.001 5.70E-07 0.585 1.231 0.000 18.763 0.402 0.778 rs55875066 HDAC4 3.887 1.02E-04 0.203 1.928 0.000 48.135 0.082 0.916 rs12696304 TERC -4.536 5.73E-06 0.719 1.147 0.000 12.795 0.493 0.839 rs251464 PPARGC1B -3.833 1.26E-04 0.083 2.058 0.000 51.417 0.039 0.833 rs12203592 IRF4 1.216 2.24E-01 3.35E-51 3.245 79.689 69.187 0.013 7.02E-6 rs1636744 TCONS_l2_00025686 3.061 2.21E-03 0.684 1.000 0.000 0.000 0.625 0.550 rs600951 DOCK8 2.590 9.59E-03 5.86E-04 2.775 1.573 63.965 0.009 0.327 rs869329 MTAP 5.490 4.01E-08 1.72E-05 -
Homozygous Deletions Implicate Non-Coding Epigenetic Marks In
www.nature.com/scientificreports OPEN Homozygous deletions implicate non‑coding epigenetic marks in Autism spectrum disorder Klaus Schmitz‑Abe1,2,3,4, Guzman Sanchez‑Schmitz3,5, Ryan N. Doan1,3, R. Sean Hill1,3, Maria H. Chahrour1,3, Bhaven K. Mehta1,3, Sarah Servattalab1,3, Bulent Ataman6, Anh‑Thu N. Lam1,3, Eric M. Morrow7, Michael E. Greenberg6, Timothy W. Yu1,3*, Christopher A. Walsh1,3,4,8,9* & Kyriacos Markianos1,3,4,10* More than 98% of the human genome is made up of non‑coding DNA, but techniques to ascertain its contribution to human disease have lagged far behind our understanding of protein coding variations. Autism spectrum disorder (ASD) has been mostly associated with coding variations via de novo single nucleotide variants (SNVs), recessive/homozygous SNVs, or de novo copy number variants (CNVs); however, most ASD cases continue to lack a genetic diagnosis. We analyzed 187 consanguineous ASD families for biallelic CNVs. Recessive deletions were signifcantly enriched in afected individuals relative to their unafected siblings (17% versus 4%, p < 0.001). Only a small subset of biallelic deletions were predicted to result in coding exon disruption. In contrast, biallelic deletions in individuals with ASD were enriched for overlap with regulatory regions, with 23/28 CNVs disrupting histone peaks in ENCODE (p < 0.009). Overlap with regulatory regions was further demonstrated by comparisons to the 127‑epigenome dataset released by the Roadmap Epigenomics project, with enrichment for enhancers found in primary brain tissue and neuronal progenitor cells. Our results suggest a novel noncoding mechanism of ASD, describe a powerful method to identify important noncoding regions in the human genome, and emphasize the potential signifcance of gene activation and regulation in cognitive and social function. -
The Role of SMARCAD1 During Replication Stress Sarah Joseph
The role of SMARCAD1 during replication stress Sarah Joseph Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2020 © 2020 Sarah Joseph All Rights Reserved Abstract The role of SMARCAD1 during replication stress Sarah Joseph Heterozygous mutations in BRCA1 or BRCA2 predispose carriers to an increased risk for breast or ovarian cancer. Both BRCA1 and BRCA2 (BRCA1/2) play an integral role in promoting genomic stability through their respective actions during homologous recombination (HR) mediated repair and stalled replication fork protection from nucleolytic degradation. SMARCAD1 (SD1) is a SWI/SNF chromatin remodeler that has been implicated in promoting long-range end resection and contributes to HR. Using human cell lines, we show that SMARCAD1 promotes nucleolytic degradation in BRCA1/2-deficient cells dependent on its chromatin remodeling activity. Moreover, SMARCAD1 prevents DNA break formation and promotes fork restart at stalled replication forks. These studies identify a new role for SMARCAD1 at the replication fork. In addition to the work presented here, I discuss a method for introducing stop codons (nonsense mutations) into genes using CRISPR-mediated base editing, called iSTOP, and provide an online resource for accessing the sequence of iSTOP sgRNASs (sgSTOPs) for five base editor variants (VQR-BE3, EQR-BE3, VRER-BE3, SaBE3, and SaKKH-BE3) in humans and over 3 million targetable gene coordinates for eight eukaryotic species. Ultimately, with improvements to CRISPR base editors this method can help model and study nonsense mutations in human disease. Table of Contents List of Figures ................................................................................................................. -
Quantitative Trait Loci Mapping of Macrophage Atherogenic Phenotypes
QUANTITATIVE TRAIT LOCI MAPPING OF MACROPHAGE ATHEROGENIC PHENOTYPES BRIAN RITCHEY Bachelor of Science Biochemistry John Carroll University May 2009 submitted in partial fulfillment of requirements for the degree DOCTOR OF PHILOSOPHY IN CLINICAL AND BIOANALYTICAL CHEMISTRY at the CLEVELAND STATE UNIVERSITY December 2017 We hereby approve this thesis/dissertation for Brian Ritchey Candidate for the Doctor of Philosophy in Clinical-Bioanalytical Chemistry degree for the Department of Chemistry and the CLEVELAND STATE UNIVERSITY College of Graduate Studies by ______________________________ Date: _________ Dissertation Chairperson, Johnathan D. Smith, PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, David J. Anderson, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Baochuan Guo, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Stanley L. Hazen, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Renliang Zhang, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Aimin Zhou, PhD Department of Chemistry, Cleveland State University Date of Defense: October 23, 2017 DEDICATION I dedicate this work to my entire family. In particular, my brother Greg Ritchey, and most especially my father Dr. Michael Ritchey, without whose support none of this work would be possible. I am forever grateful to you for your devotion to me and our family. You are an eternal inspiration that will fuel me for the remainder of my life. I am extraordinarily lucky to have grown up in the family I did, which I will never forget. -
ALKBH3 Partner ASCC3 Mediates P-Body Formation and Selective
Wollen et al. J Transl Med (2021) 19:287 https://doi.org/10.1186/s12967-021-02948-6 Journal of Translational Medicine RESEARCH Open Access ALKBH3 partner ASCC3 mediates P-body formation and selective clearance of MMS-induced 1-methyladenosine and 3-methylcytosine from mRNA Kristian Lied Wollen1,2, Lars Hagen1,2,3, Cathrine B. Vågbø1,2,3, Renana Rabe1,2, Tobias S. Iveland1,2, Per Arne Aas1,2, Animesh Sharma1,2,3, Bjørnar Sporsheim1,4, Hilde O. Erlandsen1, Vuk Palibrk1, Magnar Bjørås1, Davi M. Fonseca1,2,3, Nima Mosammaparast5 and Geir Slupphaug1,2,3* Abstract Background: Reversible enzymatic methylation of mammalian mRNA is widespread and serves crucial regulatory functions, but little is known to what degree chemical alkylators mediate overlapping modifcations and whether cells distinguish aberrant from canonical methylations. Methods: Here we use quantitative mass spectrometry to determine the fate of chemically induced methylbases in the mRNA of human cells. Concomitant alteration in the mRNA binding proteome was analyzed by SILAC mass spectrometry. Results: MMS induced prominent direct mRNA methylations that were chemically identical to endogenous meth- ylbases. Transient loss of 40S ribosomal proteins from isolated mRNA suggests that aberrant methylbases mediate arrested translational initiation and potentially also no-go decay of the afected mRNA. Four proteins (ASCC3, YTHDC2, TRIM25 and GEMIN5) displayed increased mRNA binding after MMS treatment. ASCC3 is a binding partner of the DNA/RNA demethylase ALKBH3 and was recently shown to promote disassembly of collided ribosomes as part of the ribosome quality control (RQC) trigger complex. We fnd that ASCC3-defcient cells display delayed removal of MMS- induced 1-methyladenosine (m1A) and 3-methylcytosine (m3C) from mRNA and impaired formation of MMS-induced P-bodies. -
The Neurodegenerative Diseases ALS and SMA Are Linked at The
Nucleic Acids Research, 2019 1 doi: 10.1093/nar/gky1093 The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky1093/5162471 by [email protected] on 06 November 2018 Binkai Chi, Jeremy D. O’Connell, Alexander D. Iocolano, Jordan A. Coady, Yong Yu, Jaya Gangopadhyay, Steven P. Gygi and Robin Reed* Department of Cell Biology, Harvard Medical School, 240 Longwood Ave. Boston MA 02115, USA Received July 17, 2018; Revised October 16, 2018; Editorial Decision October 18, 2018; Accepted October 19, 2018 ABSTRACT Fused in Sarcoma (FUS) and TAR DNA Binding Protein (TARDBP) (9–13). FUS is one of the three members of Understanding the molecular pathways disrupted in the structurally related FET (FUS, EWSR1 and TAF15) motor neuron diseases is urgently needed. Here, we family of RNA/DNA binding proteins (14). In addition to employed CRISPR knockout (KO) to investigate the the RNA/DNA binding domains, the FET proteins also functions of four ALS-causative RNA/DNA binding contain low-complexity domains, and these domains are proteins (FUS, EWSR1, TAF15 and MATR3) within the thought to be involved in ALS pathogenesis (5,15). In light RNAP II/U1 snRNP machinery. We found that each of of the discovery that mutations in FUS are ALS-causative, these structurally related proteins has distinct roles several groups carried out studies to determine whether the with FUS KO resulting in loss of U1 snRNP and the other two members of the FET family, TATA-Box Bind- SMN complex, EWSR1 KO causing dissociation of ing Protein Associated Factor 15 (TAF15) and EWS RNA the tRNA ligase complex, and TAF15 KO resulting in Binding Protein 1 (EWSR1), have a role in ALS.